Deal Watch: Teva's Sol Barer Leads Buyout Of IO Start-up NexImmune
Executive Summary
Instead of helping raise a Series A, the Teva chairman and others acquire the preclinical company, convinced of its synthetic nanotech promise in immuno-oncology. Vifor and ChemoCentryx expand their orphan and renal disease collaboration, while Gilead out-licenses an addiction drug candidate.
You may also be interested in...
Vifor Becomes A 'Pure Play' Pharma
A Swiss IPO for retail pharmacy and distributor spin-off Galenica Santé has allowed the remaining specialty firm Vifor Pharma to become a pure play pharma with a potential blockbuster potassium binder Veltassa and interests in renal disease, iron replacement and cardio-renal disorders.
Gilead, With Two PRVs In Hand, Holds Options For Accelerating Late-Stage Pipeline
Likely candidates for use of Gilead's priority review vouchers include GS-4997, a Phase III candidate for NASH, and bictegravir, its second-generation integrase inhibitor for HIV. The virology specialist previously used a PRV successfully to accelerate approval of Odefsey.
M&A Analysis Reveals Mid Pharma Purchase Preferences
Immunology- and inflammation-focused biotech companies wondering if a trade exit is in their future will be interested to read that, according to a report from Datamonitor Healthcare, their demographic is the most popular acquisition target of the mid-size pharma cohort.